Drug Trial Radar · NCT05517421
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
Nov 23, 2022
Primary completion
Nov 2, 2025
Study completion Nov 18, 2025
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Conditions
- Thyroid Eye Disease
Interventions
BatoclimabDrug
Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of proptosis respondersTime frame: At Week 24
Locations
93 sites in 9 countries. Site status is shown where the registry gives one.
Site Number - 1557
Beverly Hills, California
Site Number - 1539
Carlsbad, California
Site Number - 1502
Los Angeles, California
Site Number - 1505
Los Angeles, California
Site Number - 1532
Los Angeles, California
Site Number - 1537
San Diego, California
Site Number - 1531
Torrance, California
Site Number - 1501
Aurora, Colorado
Site Number - 1544
Longmont, Colorado
Site Number - 1547
Newark, Delaware
Site Number - 1504
Miami, Florida
Site Number - 1538
Port Charlotte, Florida
Site Number - 1542
Tampa, Florida
Site Number - 1536
West Palm Beach, Florida
Site Number - 1554
Stockbridge, Georgia
Site Number - 1534
Chicago, Illinois
Site Number - 1545
Iowa City, Iowa
Site Number - 1535
Baltimore, Maryland
Site Number - 1506
Boston, Massachusetts
Site Number - 1540
Las Vegas, Nevada
Site Number - 1530
Chapel Hill, North Carolina
Site Number - 1550
Columbus, Ohio
Site Number - 1507
Portland, Oregon
Site Number - 1556
Warwick, Rhode Island
Site Number - 1551
Dallas, Texas
Site Number - 1508
Houston, Texas
Site Number - 1558
Mesquite, Texas
Site Number - 1500
Roanoke, Virginia
Site Number - 1509
Madison, Wisconsin
Site Number - 2502
Edmonton, Alberta, Canada
Site Number - 2500
Ottawa, Ontario, Canada
Site Number - 2501
Montreal, Quebec, Canada
Site Number - 3452
Tbilisi, Georgia
Site Number - 3454
Tbilisi, Georgia
Site Number - 3455
Tbilisi, Georgia
Site Number - 3450
Tbilisi, Georgia
Site Number - 3451
Tbilisi, Georgia
Site Number - 3453
Tbilisi, Georgia
Site Number - 6611
Schwerin, Germany
Site Number - 6609
Tübingen, Baden - Wuttemberg, Germany
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.